LTZ Therapeutics
LTZ Therapeutics is a biotech company focused on immunotherapy, developing novel therapies to improve outcomes for cancer and autoimmune disease patients. Their Myeloid Engager Platform enhances the body's immune response to fight disease, leveraging reverse translational science and a deep understanding of tumor microenvironment biology. The company's lead asset, LTZ-301, is advancing towards Phase 1 clinical trials.
Funding Round: Series A
Funding Amount: $20M
Date: 30-Jul-2024
Investors: Lapam Capital, GL Ventures, K2 Venture Partners, Shunwei Capital
Markets: Biotechnology, Immunotherapy, Oncology, Autoimmune Diseases, Health Care, Medical, Drug Discovery
HQ: Redwood City, California, United States
Founded: 2022
Website: https://www.ltztherapeutics.com/
LinkedIn: https://www.linkedin.com/company/ltz-therapeutics
Crunchbase: https://www.crunchbase.com/organization/ltz-therapeutics
Leave a Comment
Comments
No comments yet.